Rundle Charles H, Wang Xiaoguang, Wergedal Jon E, Mohan Subburaman, Lau K-H William
Musculoskeletal Disease Center, Jerry L. Pettis Memorial Veterans Administration Medical Center, 11201 Benton Street, Loma Linda, CA 92357, USA.
Calcif Tissue Int. 2008 Oct;83(4):276-84. doi: 10.1007/s00223-008-9169-7. Epub 2008 Sep 27.
To evaluate the role of plasminogen activator inhibitor (PAI)-1, a key negative regulator of the plasmin system of extracellular matrix proteases in developmental bone growth and fracture repair, the bone phenotype of male adult PAI-1-deficient mice was determined and femoral fracture healing was compared with that of age- and sex-matched wild-type C57BL/6J control mice. Regarding bone phenotype, the length and size (but not cortical thickness) of the femur of male PAI-1-deficient mice were smaller than those of wild-type controls. Although the total bone mineral content of PAI-1-deficient mice was not significantly different from that of wild-type mice, the total bone area in PAI-1-deficient mice was smaller, leading to an increase in total bone mineral density. With respect to fracture healing, PAI-1-deficient mice developed fracture calluses that were larger and more mineralized than those of wild-type mice but only at 14 days postfracture. These changes were even greater given the smaller size of the normal femur in PAI-1-deficient mice. Surprisingly, the larger fracture callus remodeled rapidly to normal size and mineral content by 21 days postfracture. Examination of fracture histology revealed that these changes were associated with a dramatic increase followed by a rapid remodeling of the fracture callus cartilage. The remodeling of fracture callus cartilage in PAI-1-deficient mice also displayed an abnormal pattern. These findings demonstrate for the first time that PAI-1 (and potentially the plasminogen extracellular matrix protease system) is an important regulator of bone size during developmental growth and plays a regulatory role in the determination of fracture callus size, cartilage formation, and resorption during bone fracture repair.
为了评估纤溶酶原激活物抑制剂(PAI)-1在骨骼发育生长和骨折修复过程中细胞外基质蛋白酶纤溶酶系统的关键负调控因子的作用,我们测定了成年雄性PAI-1缺陷小鼠的骨骼表型,并将其股骨骨折愈合情况与年龄和性别匹配的野生型C57BL/6J对照小鼠进行了比较。关于骨骼表型,雄性PAI-1缺陷小鼠股骨的长度和大小(但皮质厚度无差异)小于野生型对照小鼠。虽然PAI-1缺陷小鼠的总骨矿物质含量与野生型小鼠无显著差异,但PAI-1缺陷小鼠的总骨面积较小,导致总骨矿物质密度增加。关于骨折愈合,PAI-1缺陷小鼠形成的骨折痂比野生型小鼠的更大且矿化程度更高,但仅在骨折后14天时如此。鉴于PAI-1缺陷小鼠正常股骨尺寸较小,这些变化更为明显。令人惊讶的是,到骨折后21天时,较大的骨折痂迅速重塑为正常大小和矿物质含量。骨折组织学检查显示,这些变化与骨折痂软骨的急剧增加随后迅速重塑有关。PAI-1缺陷小鼠骨折痂软骨的重塑也呈现出异常模式。这些发现首次证明,PAI-1(以及潜在的纤溶酶原细胞外基质蛋白酶系统)在发育生长过程中是骨骼大小的重要调节因子,并且在骨折修复过程中对骨折痂大小、软骨形成和吸收的确定起调节作用。